Rafael Holdings, Inc. is a company that holds interests in clinical and early stage pharmaceutical businesses, and commercial real estate in the US and Israel. The company operates in two segments, Pharmaceuticals and Real Estate, by leasing commercial spaces and developing therapies for cancer treatment. Its lead drug candidate, CPI-613 (devimistat), is being trialed in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia.